Regenerative Patch Technologies Begins Phase IIb Trial for Macular Degeneration Treatment
Regenerative Patch Technologies (RPT) has announced the treatment of the first two patients in a Phase IIb clinical trial aimed at assessing the safety and efficacy of its allogeneic bioengineered RPE cell implant for advanced dry age-related macular degeneration (AMD). This trial, conducted at multiple sites in California, Illinois, and Texas, seeks to build on the safety and efficacy data from a previous Phase I/IIa study. The earlier trial showed promising results, with 27% of treated eyes experiencing significant visual acuity improvements. The Phase IIb trial will utilize a cryopreserved formulation of the implant, facilitating easier shipment and storage. 
